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Objective: Fructose-1,6-bisphosphate is a high-energy intermediate in the anaerobic
metabolism. It enhances glycolysis, preserves cellular adenosine triphosphate, and
prevents the increase of intracellular calcium during ischemia. The potential neu-
roprotective effect of fructose-1,6-bisphosphate during hypothermic circulatory
arrest was evaluated in a surviving porcine model.
Methods: Twenty-four pigs were randomly assigned to receive two intravenous
infusions of either fructose-1,6-bisphosphate (500 mg/kg) or saline solution. The
first infusion was given immediately before a 75-minute period of hypothermic
circulatory arrest and the second was given immediately after hypothermic circu-
latory arrest.
Results: The 7-day survivals were 83.3% in the fructose-1,6-bisphosphate group and
41.7% in the control group (P  .09). The treated animals had significantly better
postoperative behavioral scores. The administration of fructose-1,6-bisphosphate
was associated with higher venous phosphate and sodium levels, lower venous
ionized calcium levels, higher blood osmolarity, and a better fluid balance. Intra-
cranial pressure and venous creatine kinase isoenzyme MB were significantly lower
in the fructose-1,6-bisphosphate group during rewarming (P  .01 and P  .001,
respectively). Among the treated animals, brain glucose, pyruvate and lactate levels
tended to be higher, brain glycerol levels tended to be lower, and the histopathologic
score of the brain was significantly lower (P  .04).
Conclusions: Intravenous administration of fructose-1,6-bisphosphate at 500 mg/kg
before and after hypothermic circulatory arrest in a surviving porcine model was
associated with better survival, behavioral outcome, and histopathologic score. The
observed lower blood creatine kinase isoenzyme MB and brain glycerol levels and
the higher brain glucose, pyruvate, and lactate levels in the fructose-1,6-bisphos-
phate group suggest that this drug has supportive effects on myocardial and brain
metabolisms.
Impairment of oxidative metabolism during brain ischemia is associatedwith adenosine triphosphate (ATP) deficit and subsequent intracellularcalcium ion accumulation, which are considered the main factors leading tosevere brain injury. Fructose-1,6-bisphosphate (FDP) is an intermediate inanaerobic glycolysis. It increases the activity of phosphofructokinase, a keyenzyme in glycolysis, and of pyruvate kinase and thus enhances glycolysis.
Exogenously administered FDP can be metabolized anaerobically. It is a high-
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energy metabolite, because it releases 4 mol ATP for 1 mol
FDP, whereas only 2 mol ATP is formed by anaerobic
metabolism of 1 mol glucose. FDP has also been shown to
decrease calcium uptake into the cell during ischemia.1,2
Several studies have demonstrated that FDP reduces
myocardial tissue damage induced by ischemia and reper-
fusion.2-4 There is also some in vitro evidence that FDP
prevents the loss of ATP and protects astrocytes from hy-
poxic injury.5 Moreover, the neuroprotective effect of FDP
has been observed in several animal models of brain isch-
emia.6,7 However, negative results with the use of FDP have
also been reported.8,9 We performed this study to evaluate
whether FDP has neuroprotective effects in a surviving
porcine model of hypothermic circulatory arrest (HCA).
Material and Methods
Twenty-four female juvenile pigs (age 8-10 weeks) of a native
stock were randomly assigned to receive two intravenous infusions
of either FDP at 500 mg/kg or 0.9% sodium chloride solution. The
first infusion of 15-minute duration was given just before a 75-
minute period of HCA, and the second infusion of 30-minute
duration was given immediately at the start of reperfusion.
Preoperative Management
All animals received humane care in accordance with the “Prin-
ciples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the Guide for the Care and Use
of Laboratory Animals prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996. The study was ap-
proved by the Research Animal Care and Use Committee of the
University of Oulu.
Anesthesia and Hemodynamic Monitoring
Anesthesia was induced with ketamine hydrochloride (10 mg/kg
administered intramuscularly) and midazolam (1 mg/kg adminis-
tered intramuscularly). A peripheral venous catheter was inserted
into the right ear for administration of drugs and to maintain fluid
balance with Ringer acetate solution. Anesthesia was deepened
with thiopental sodium (125-250 mg administered intravenously),
and pancuronium bromide (4 mg administered intravenously) was
given for muscular paralysis. Cefuroxime (1.5 g) was given as
antibiotic prophylaxis at the induction of anesthesia and before
extubation 8 hours after the start of rewarming.
After endotracheal intubation, the animals were maintained on
positive-pressure ventilation with 50% oxygen, and anesthesia was
maintained with isoflurane (1.2%-1.3%). Electrocardiographic
monitoring was started. An arterial catheter was positioned into the
left femoral artery for arterial pressure monitoring and blood
sampling. A thermodilution catheter (CritiCath 7F; Ohmeda
GmbH & Co, Erlangen, Germany) was placed through the left
femoral vein for blood collection, pressure monitoring in the
pulmonary artery, and recording of blood temperature and cardiac
output. A 10F catheter was placed into the urinary bladder for
monitoring of urine output. Blood, rectal, esophageal, epidural,
and intracerebral temperatures were monitored continuously.
Brain Microdialysis and Intracerebral Monitoring
A temperature probe was placed into the epidural space through a
cranial hole made on the left side anteriorly to the coronal suture.
A catheter for measurement of intracerebral tissue oxygen partial
pressure (Revodoxe Brain Oxygen Catheter-Micro-Probe, ref.
CC1.SB; GMS Gesellschaft fu¨r medizinische Sondentechnik mbH,
Mielkendorf, Germany) was inserted through a hole located on the
right side anteriorly to the coronal suture. Another temperature
probe (Thermocouple Temperature Catheter-Micro-Probe, ref.
C8.B; GMS) for the measurement of intracerebral temperature,
together with an intracranial pressure-monitoring catheter (Cod-
man Micro-Sensor ICP Transducer; Codman & Shurtleff, Inc,
Raynham, Mass), were placed through a hole located on the left
side posteriorly to the coronal suture. Intracerebral temperature
and brain tissue oxygen partial pressure were monitored with
Licox CMP Monitor (GMS). Intracranial pressure was monitored
with Codman ICP Express Monitor (Codman & Shurtleff).
The microdialysis catheter (CMA 70; CMA/Microdialysis,
Stockholm, Sweden) was placed into the brain cortex to a depth of
15 mm below the dura mater through a hole located on the right
side posteriorly to the coronal suture. The catheter was connected
to a 2.5-mL syringe placed into a microinfusion pump (CMA 106;
CMA/Microdialysis) and perfused with Ringer solution (Perfusion
Fluid CNS; CMA/Microdialysis). Samples were collected at dif-
ferent time points. The brain tissue concentrations of glucose,
lactate, pyruvate, glutamate, and glycerol were measured immedi-
ately after collection by ordinary enzymatic methods with a mi-
crodialysis analyzer (CMA 600; CMA/Microdialysis).
Electroencephalographic Monitoring
Cortical electrical activity was registered by four stainless-steel
screw electrodes 5 mm in diameter implanted in the skull over the
parietal and frontal areas of the cortex with a digital electroen-
cephalographic (EEG) recorder (Nervus, Reykjavik, Iceland) and
an amplifier (Magnus EEG 32/8, Reykjavik, Iceland). Sampling
frequency was 256 Hz, and bandwidth was 1.6 to 70 Hz. All four
EEG electrodes were referenced to another screw electrode, which,
together with a ground screw electrode, was implanted over the
frontal sinuses.
The isoflurane level was adjusted so that the EEG showed a
steady burst-suppression pattern. Isoflurane end-tidal concentra-
tion was kept at this steady level until the end of monitoring. The
EEG tracing was recorded for 10 minutes before the cooling
perfusion to get a baseline recording of steady burst-suppression
activity. After HCA, EEG recording was restarted and continued
until extubation. The duration of bursts were measured from
5-minute EEG samples at 1-hour intervals with a custom automatic
analysis program. Artifact periods were excluded from each
5-minute sample, and after that the sum of burst durations was
counted as a percentage of the sum of artifact-free EEG in this
sample. This percentage was used as a measure of EEG activity in
the analysis.
Cardiopulmonary Bypass
Through a right thoracotomy in the fourth intercostal space, the
right internal thoracic vessels were ligated, the pericardium was
opened, and the heart and the great vessels were exposed. A
membrane oxygenator (Midiflow D 705; Dideco SpA, Mirandola,
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Italy) was primed with 1 L Ringer acetate and heparin (5000 IU).
After systemic heparinization (500 IU/kg), the ascending aorta was
cannulated with a 16F arterial cannula, and the right atrial append-
age was cannulated with a single 24F atrial cannula. Nonpulsatile
cardiopulmonary bypass (CPB) was initiated and maintained with
100% oxygen during cooling and rewarming periods at a flow rate
of 100 mL/(kg  min). The CPB flow was adjusted to maintain a
perfusion pressure of 50 mm Hg. A 12F intracardiac sump cannula
was positioned in the left ventricle through the apex of the heart for
decompression of the left side of the heart during CPB. A heat
exchanger was used for core cooling. The pH was maintained with
alpha-stat principles at 7.40  0.05, with PaCO2 at 4.0 to 5.0 kPa
uncorrected for temperature.
Drug Administration
The molecular weight of FDP is 336.082 kd. The drug (Esafosfina;
Biomedica Foscama Industria Chimico-Farmaceutica SpA, Fe-
rentino, Italy) was stored at room temperature in 100-mL bottles
containing FDP (100 g/L), inorganic phosphate ion (46 mmol/L,
1.43 g), sodium ion (44 mmol/L, 2.64 g), and fructose (22 mmol/L,
4.0 g). The liquid was sterile and colorless, its pH was 3.5 to 3.8,
and its osmolarity was 620 mmol/L. Before infusion, the drug was
neutralized with sodium hydroxide (34 mL sodium hydroxide per
200 mL FDP) to yield a pH of 6.3. The sodium hydroxide solution
contained sodium ion at 2 mol/L. The placebo consisted of a
corresponding volume (5 mL/kg) of isotonic sodium chloride
(sodium ion at 150 mmol/L) with a pH of 6.0 to 6.5. The drug and
placebo solutions were administered intravenously in a random-
ized, double-blinded fashion.
Experimental Protocol
After baseline measurements, the cannulations of the heart and
aorta were done. A cooling period of 60 minutes was carried out
to attain an intracerebral temperature of 18°C. After 45 minutes of
cooling, the first infusion of the drug (FDP 500 mg/kg) or placebo
was started, and it was administered during a 15-minute period.
The ascending aorta was crossclamped just distal to the aortic
cannula, cardiac arrest was induced by injecting potassium chlo-
ride (3 g) through the aortic cannula, and a 75-minute period of
HCA was started. Topical cardiac cooling with ice slush was
begun and maintained throughout the HCA period, and the intra-
cerebral temperature was maintained at a level of 18°C with ice
packs placed over the head. After 75-minutes of HCA, reperfusion
and rewarming were commenced, and at the same time a second
infusion of the drug (FDP 500 mg/kg) or placebo was started, and
it was administered during a 30-minute period. The animals were
rewarmed to a core temperature of 37°C during 60 minutes of
reperfusion, and this temperature was maintained until the end of
the experiment. The temperatures were regulated with heat-ex-
changer mattress, heating lamps, and ice packs.
During rewarming, the left ventricular sump cannula was re-
moved, and furosemide (40 mg), mannitol (15 g), methylpred-
nisolone (80 mg), lidocaine (40-160 mg), and calcium glubionate
(1375 mg) were administered. After weaning from CPB, cardiac
support was provided with dopamine. The animals were kept under
anesthesia with isoflurane. They were ventilated with 100% oxy-
gen until 2 hours after the start of rewarming, and after that with
50% oxygen until the extubation which occurred 8 hours after the
start of rewarming. After extubation the animals were moved to a
recovery room.
During the experiment, hemodynamic and metabolic measure-
ments were recorded continuously or at baseline, at the end of
cooling (immediately before institution of HCA), and 30 minutes,
2 hours, 4 hours, and 8 hours after the start of rewarming. Pulse
rate, systemic and pulmonary arterial pressures, central venous
pressure, pulmonary capillary wedge pressure, cardiac output,
intracranial pressure, intracerebral tissue PO2, and temperatures
were monitored. Arterial and venous pH values, PaO2, PCO2, oxy-
gen saturation, oxygen concentration, hematocrit, hemoglobin, so-
dium, potassium, and glucose were measured with the Ciba-Corn-
ing 288 Blood Gas System (Ciba-Corning Diagnostic Corp,
Medfield, Mass). Lactate was measured with the YSI 1500 ana-
lyzer (YSI Incorporated, Yellow Springs, Ohio). Leukocyte dif-
ferential counts were performed with the Cell-Dyn analyzer (Ab-
bot, Santa Clara, Calif). Ionized calcium and phosphate were
measured with the Cobas Integra (Roche Diagnostics Division,
Basel, Switzerland). Pyruvate was measured with the Hitachi 911
(Roche Diagnostics GmbH, Mannheim, Germany). Creatine ki-
nase (CK) and its isoenzymes (CK-MM, CK-MB, and CK-BB)
were measured with the Hydrasys LC-electrophoresis Hyrys-den-
sitometer (SEBIA France, Issy-les-Moulineaux, France).
Postoperative Evaluation
After the operation all the animals were evaluated on daily basis
with a species-specific quantitative behavioral score by an expe-
rienced observer who was blinded to the study group. The assess-
ment quantified mental status (0, comatose; 1, stuporous; 2, de-
pressed; 3, normal), appetite (0, refuses liquids; 1, refuses solids;
2, decreased; 3, normal), and motor function (0, unable to stand; 1,
unable to walk; 2, unsteady gait; 3, normal). Numeric summing of
these functions provided a final score, with a maximum score of 9
reflecting apparently normal neurologic function and lower values
indicating substantial brain damage.
Perfusion Fixation
Each surviving animal was electively killed on the seventh post-
operative day. Immediately after intravenous injection of pento-
barbital (60 mg/kg) and heparin (500 IU/kg), the thoracic cavity
was opened, and the descending thoracic aorta was clamped.
Ringer solution (1 L) was infused through the ascending thoracic
aorta through the upper body, and blood was suctioned from the
superior vena cava until the perfusate was clear of blood. Then
10% formalin solution (1 L during 15 minutes) was perfused
through the brain in the same manner to accomplish a perfusion
fixation. Immediately thereafter the entire brain was removed,
weighed, and immersed in 10% neutral formalin. The same
method of fixation procedure was carried out in those animals that
died before the seventh postoperative day.
Histopathologic Analysis
The brain was allowed to fix in formalin for 1 week en bloc.
Thereafter, 3-mm thick coronal samples were sliced from the left
frontal lobe, thalamus (including the adjacent cortex), and hip-
pocampus (including the adjacent brainstem and temporal cortex),
and sagittal samples were sliced from the posterior brainstem
(medulla oblongata and pons) and cerebellum. The specimens
Cardiopulmonary Support and Physiology Romsi et al
688 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
CSP
were fixed in fresh formalin for another week. After fixation, the
samples were processed as follows: rinsing in water for 20 minutes
and immersion in 70% ethanol for 2 hours, immersion in 94%
ethanol for 4 hours, and immersion in absolute ethanol for 9 hours.
The specimens were then kept for 1 hour in absolute ethanol-
xylene mixture and 4 hours in xylene and embedded in warm
paraffin for 6 hours. The specimens were sectioned at 6 m and
stained with hematoxylin and eosin. The sections of the brain
specimens of each animal were screened by an experienced senior
pathologist (J.H.), who was unaware of the experimental design
and of the identity and fate of each individual animal. Each section
was carefully examined for the presence or absence of any isch-
emic or other kinds of tissue damage.
The signs of injury were scored as follows: 1, dark or eosino-
philic neurons or cerebellar Purkinje cells; 2, moderate edema; and
3, severe edema or infarct foci (local necrosis). A total histopatho-
logic score was calculated by summing the scores of each specific
brain area (cortex, thalamus, hippocampus, posterior brainstem,
and cerebellum) to allow semiquantitative comparisons among the
animals. The histopathologic score in this study was determined
according to a commentary to the article by Rimpila¨inen and
colleagues.10
Statistical Analysis
Statistical analysis was performed with SPSS software (SPSS
version 10.0; SPSS Inc, Chicago, Ill). Values are expressed as the
median with interquartile ranges (25th-75th percentile). Differ-
ences in survival outcomes in the study groups were evaluated
with the Fisher exact test. Differences between the study groups
were determined with the t test or the Mann-Whitney test. Vari-
ance analysis of repeated measurements was used, and the results
of the tests of between-subjects effects and of interactions between
time versus baseline and other intervals in these two groups were
reported.
Results
Comparability of the Groups
The median weights of the pigs were 30.5 kg (interquartile
range 29.4-31.6 kg) in the FDP group and 28.6 kg (inter-
quartile range 27.0-30.4 kg) in the control group (P  .03).
However, there was no statistically significant difference in
weight between the pigs that died before the seventh post-
operative day and those that survived (median 28.1 kg vs
30.2 kg, P .11). The median CPB cooling times were 61.0
minutes (interquartile range 60.0-60.3 minutes) in the FDP
group and 61.0 minutes (interquartile range 60.3-62.0 min-
utes) in the control group (P  .84). The median CPB
rewarming times were 63.5 minutes (interquartile range
61.3-68.3 minutes) in the FDP group and 63.0 minutes
(interquartile range 62.3-69.3 minutes) in the control group
(P  .89). The median total CPB times were 126.0 minutes
(interquartile range 123.5-134.3 minutes) in the FDP group
and 124.5 minutes (interquartile range 123.3-129.8 minutes)
in the control group (P  .67). During the experiment the
intracerebral temperatures did not differ between the study
groups (Figure 1).
Mortality and Behavioral Outcome
The 7-day survivals were 83.3% in the FDP group and
41.7% in the control group (P  .09). The postoperative
behavioral scores of the animals are presented in Figure 2.
P values for comparisons between the groups on each
postoperative day (from the first through the seventh) in
surviving animals were as follows: P  .001, P  .27, P 
.03, P .05, P .09, P .004, and P .004, respectively.
The sums of behavioral score from each postoperative day
Figure 1. Intracerebral temperatures in pigs during experimental protocol in FDP (squares) and control (circles)
groups. Data points represent medians; error bars represent interquartile ranges (25th-75th percentile).
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in animals surviving at 7 days were significantly different
between the groups (44.4 in the FDP group and 34.6 in the
control group, P  .01).
Hemodynamic and Metabolic Data
Hemodynamic and metabolic data are presented in Tables 1
and 2 and in Figure 3. There were no significant differences
between the study groups in terms of cardiac indices, mean
arterial pressures, and hemoglobin levels. After the admin-
istration of FDP, there was a significant increase in serum
phosphate level (P  .001) and a significant decrease in
serum ionized calcium level (P  .001). The drug also
increased the serum sodium level so that the osmolarity was
significantly higher in the FDP group (P  .001). This also
led to an increased diuresis rate and a better fluid balance in
the FDP group during the postoperative period (P  .03).
The animals in the FDP group had significantly higher
blood glucose levels at the 2-hour interval after the start of
rewarming (P  .03). Serum potassium was significantly
lower in the FDP group at extubation (P  .007), possibly
as a result of increased diuresis. Vascular resistance was
lower in the FDP group throughout the experiment (P 
.05).
There where no statistically significant differences be-
tween the study groups in terms of blood pyruvate levels or
blood lactate-pyruvate ratio. However, blood lactate was
significantly lower in the FDP group at the end of cooling
(P  .03).
The administration of the drug caused mild and short-
lasting decreases in arterial and venous pH levels, which
reached statistical significance at the end of cooling period
(P .02 and P .04, respectively). Also, PaCO2 was higher
in the FDP group at the end of cooling. Mixed venous PO2
and oxygen saturation were significantly lower (P  .001)
and oxygen extraction was higher (P  .001) in the FDP
group at the 2-hour interval after the start of rewarming, at
the same time that mean arterial pressure and cardiac index
tended to be lower in this group.
Venous total CK and CK-MM levels were significantly
lower in the FDP group at extubation (P .04 and P .05,
respectively). Venous CK-BB levels were higher in the FDP
group at the end of cooling (P  .009). Venous CK-MB
levels were lower in the FDP group throughout the postop-
erative period. This difference was statistically significant at
30-minute interval after the start of rewarming (P  .001).
Intracranial Measurements
Intracranial measurement data are presented in Figure 4.
Brain glucose tended to be higher in the FDP group during
the first hours after the start of rewarming. Brain lactate also
tended to be higher in the FDP group from the 90-minute
interval until the 4-hour interval after the start of rewarming.
Figure 2. Daily scores from each animal in FDP (A) and control (B) groups indicating behavioral recovery after 75
minutes of HCA. Score of 9 indicates essentially complete recovery.
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Brain pyruvate levels were significantly higher in the FDP
group at the end of the rewarming period (P  .01) and
tended to be higher in this group also from the 2-hour
interval after the start of rewarming until extubation. Brain
lactate-glucose ratio showed no differences between the
study groups, whereas brain lactate-pyruvate ratio was sig-
nificantly lower in the FDP group at the end of rewarming
(43.4 in the FDP group vs 59.2 in the control group, P 
.008). Brain glycerol tended to be lower in the FDP group
during the first postoperative hours, whereas brain gluta-
mate levels were similar between the groups. The maximum
values of the brain microdialysis measurements showed the
only difference between the groups in lactate levels, which
were slightly but not significantly higher in the FDP group
(10.0 mmol/L in the FDP group vs 7.7 mmol/L in the
control group, P  .08).
Brain tissue PO2 did not differ between the groups at any
time point except at the end of cooling, when it was lower
in the FDP group (P  .04; Table 1). At that point cerebral
perfusion pressure was slightly but not significantly lower in
that group (44 mm Hg in the FDP group vs 48 mm Hg in the
control group, P  .23). Intracranial pressure levels were
significantly lower in the FDP group during rewarming
(P  .01; Figure 4).
Electroencephalographic Findings
There were no statistically significant differences between
the study groups in the EEG burst-suppression ratios at
TABLE 1. Experimental data
Baseline End of cooling
After start of rewarming
P value30 min 2 h 4 h 8 h
Mean arterial pressure (mm Hg)
FDP 73 (70-81) 52 (50-55) 60 (54-69) 62 (56-66) 60 (58-66) 64 (54-70) .27
Control 77 (69-85) 56 (53-65) 61 (56-65) 65 (61-69) 66 (59-71) 62 (58-67)
Cardiac index (L/[min  m2])
FDP 4.2 (3.9-4.4) 3.0 (2.7-3.5) 3.4 (3.1-3.9) 4.1 (3.9-5.2) 4.1 (3.8-4.5) 3.9 (3.6-4.1) .99
Control 4.0 (3.3-4.7) 3.1 (3.0-3.4) 3.5 (3.1-3.6) 4.6 (4.4-5.5) 4.3 (4.1-4.7) 3.9 (3.1-3.9)
Dopamine administration (mg/h)
FDP — — — 6.3 (3.1-7.8) 5.8 (3.3-8.4) 5.8 (4.0-8.4) —
Control — — — 4.6 (4.0-5.8) 4.5 (2.3-5.9) 5.3 (3.3-7.8)
Hemoglobin (g/L)
FDP 99 (94-104) 69 (65-71) 74 (68-81) 89 (76-105) 83 (77-100) 87 (74-92) .40
Control 98 (89-101) 68 (61-74) 74 (63-84) 85 (75-91) 86 (75-92) 85 (73-90)
Vascular resistance (dyne  s  cm5)
FDP 1605 1563 1565 1297 1340 1486 .05
Control 1668 1674 1623 1296 1386 1670
Fluid balance (mL)
FDP 200 (0-300) 2000 (1700-2500) 1900 (1300-2200)† 1600 (1200-2200)† 1400 (700-1700)† 1100 (800-1400)† .03
Control 100 (0-300) 2000 (1800-2300) 2200 (2100-2400)† 2200 (1700-3100)† 1900 (1400-2400)† 1500 (1000-2700)†
Venous total CK (U/L)
FDP 1216 (918-2596) 1666 (1283-2338) 3257 (1949-4587) 7278 (4602-9370) 8484 (5912-10693) 8107 (6516-12,518)‡ .62
Control 1783 (1583-4229) 2640 (1531-4941) 3987 (2346-5986) 8174 (5316-11744) 11,450 (8348-15,351) 12,129 (8102-18,215‡
Venous CK-MM (U/L)
FDP 884 (595-2266) 1449 (1056-2132) 3019 (1719-4294) 6745 (4168-8765) 7725 (5382-10,118) 7606 (6136-11,927)‡ .63
Control 1473 (1377-3979) 2470 (1389-4798) 3554 (1967-5626) 7528 (4712-11,253) 10877(7992-14,542) 11,341 (7415-15,355)‡
Venous CK-MB (U/L)
FDP 25 (19-33) 33 (28-47) 42 (32-56)§ 81 (65-161) 114 (66-201) 103 (68-200) .11
Control 35 (27-60) 34 (27-56) 78 (61-125)§ 114 (71-146) 154 (134-224) 163 (117-255)
Venous CK-BB (U/L)
FDP 247 (137-291) 145 (112-164)§ 158 (134-172) 368 (303-422) 404 (293-525) 289 (218-439) .34
Control 154 (137-240) 100 (73-119)§ 165 (135-228) 289 (193-379) 331 (191-402) 312 (162-417)
Brain tissue oxygen pressure (mm Hg)
FDP 27 (20-29) 38 (18-50)† 21 (16-25) 22 (18-43) 20 (15-31) 24 (18-45) .85
Control 23 (17-31) 39 (14-89)† 29 (21-56) 29 (24-38) 20 (15-28) 25 (18-37)
Values are shown as medians with interquartile ranges (25th-75th percentile). P values between groups are according to the tests of between-subjects
effects.
*Fluid balance represents fluids given intravenously minus cumulative diuresis.
†P  .05 interaction between time versus baseline and other intervals in the study groups.
‡P  .05 FDP group versus control group.
§P  .01 FDP group versus control group.
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baseline or after the start of reperfusion. However, the
animals in the FDP group tended to have somewhat quicker
recovery of EEG to normal activity level during the post-
operative period (Figure 5).
Histopathologic Data
The brain histopathologic scores are presented in Table 3
and in Figure 6. The total histopathologic score among the
animals of the FDP group was significantly lower than that
among the control animals (3.42 vs 6.08, respectively, P 
.04). Also, the scores from the thalamus (P  .01) and the
hippocampus (P  .04) showed statistically significant dif-
ferences between the groups, with the FDP group having
lower scores in these brain regions. The total score from
dark or eosinophilic neurons or cerebellar Purkinje cells
from different brain regions (cortex, thalamus, hippocam-
pus, posterior brainstem, and cerebellum) and this score
from the thalamus alone were lower in the FDP group (P 
.02 and P  .03, respectively), as was the edema score in
the cortex (P  .04).
Discussion
During the last few years we have tested in this surviving
model of HCA several strategies aimed at attenuating the
brain injury that occurs during the reperfusion phase.11-14
The use of FDP in this study was predicated on the need to
develop a protective strategy also able to cover phases of the
ischemic injury process other than reperfusion. Indeed, FDP
seems to provide metabolic support to the brain during the
ischemic phase, with beneficial effects extending to the
reperfusion period.5-7 Of great importance is the fact that
FDP also can provide metabolic support to other important
TABLE 2. Metabolic data
Baseline End of cooling
After start of rewarming
P value30 min 2 h 4 h 8 h
Arterial pH
FDP 7.50 (7.49-7.53) 7.37 (7.33-7.45)* 7.36 (7.32-7.42) 7.45 (7.43-7.48) 7.52 (7.50-7.54) 7.55 (7.52-7.57) .47
Control 7.52 (7.48-7.56) 7.45 (7.43-7.48)* 7.39 (7.32-7.42) 7.44 (7.39-7.47) 7.50 (7.48-7.54) 7.53 (7.50-7.54)
Venous pH
FDP 7.46 (7.44-7.49) 7.35 (7.32-7.42)* 7.33 (7.27-7.37) 7.40 (7.39-7.43) 7.48 (7.47-7.49) 7.50 (7.46-7.51) .74
Control 7.48 (7.42-7.51) 7.41 (7.38-7.43)* 7.31 (7.25-7.36) 7.40 (7.36-7.42) 7.46 (7.44-7.48) 7.48 (7.45-7.49)
PaCO2 (kPa)
FDP 5.1 (5.0-5.2) 5.8 (4.9-6.4) 4.7 (4.4-4.9) 5.4 (5.1-5.7) 5.3 (5.2-5.5) 5.3 (5.0-5.7) .03
Control 5.1 (4.8-5.4) 5.2 (4.4-5.5) 4.7 (4.4-5.0) 5.3 (5.0-5.6) 5.1 (4.9-5.4) 5.3 (5.0-5.5)
PvCO2 (kPa)
FDP 6.1 (5.8-6.3) 6.2 (5.4-6.8) 5.7 (5.2-6.2) 6.5 (6.3-6.8) 6.3 (6.1-6.7) 6.4 (6.2-6.8) .73
Control 6.1 (6.0-6.5) 5.9 (5.3-6.2) 5.8 (5.3-6.5) 6.5 (6.1-6.7) 6.3 (6.1-6.6) 6.5 (6.2-6.8)
PaO2 (kPa)
FDP 30.1 (27.0-36.1) 123 (108-127) 54.9 (51.9-72.8) 73.3 (64.2-79.7) 30.4 (26.8-36.1) 31.6 (27.4-37.3) .44
Control 37.2 (32.3-39.5) 114 (110-123) 63.0 (58.2-66.2) 75.2 (66.4-80.5) 30.4 (28.9-34.0) 30.2 (27.9-34.3)
PvO2 (kPa)
FDP 6.3 (5.8-6.6) 49.1 (41.5-53.3) 6.9 (6.3-7.2)* 6.2 (5.9-6.5)† 5.3 (4.8-5.4) 4.7 (4.3-5.1) .88
Control 5.9 (5.5-6.3) 52.6 (38.7-56.4) 6.9 (6.4-7.5)* 7.2 (6.5-7.6)† 5.3 (4.9-5.4) 4.6 (4.5-4.9)
Mixed venous oxygen saturation (%)
FDP 83.7 (81.6-87.3) 99.8 (99.7-99.8) 84.1 (82.0-85.7)* 82.0 (78.6-84.4)† 77.1 (71.1-79.8) 71.9 (66.6-74.8) .99
Control 83.0 (77.7-84.9) 99.8 (99.7-99.8) 82.9 (80.4-86.1)* 87.0 (84.9-88.4)† 76.6 (73.3-77.4) 71.0 (67.1-71.9)
Oxygen extraction (mL/dL)
FDP 2.7 (2.2-3.0) 1.6 (1.4-1.9)* 2.9 (2.5-3.5) 3.6 (2.9-4.3)† 3.3 (2.7-3.9) 3.8 (3.2-4.7) .55
Control 3.0 (2.7-3.4) 1.5 (1.4-1.6)* 2.7 (2.6-3.2) 3.0 (2.9-3.4)† 3.3 (3.0-3.8) 4.0 (3.6-4.3)
Venous glucose (mmol/L)
FDP 6.0 (5.3-7.4) 6.0 (5.7-6.9) 13.4 (11.7-15.4) 10.4 (8.9-12.6)* 9.0 (8.0-10.3) 7.1 (6.7-8.5) .38
Control 5.9 (5.6-6.5) 7.0 (5.1-7.5) 13.5 (12.1-14.9) 8.8 (7.6-9.9)* 8.0 (7.3-9.1) 7.4 (6.9-8.0)
Venous lactate (mmol/L)
FDP 1.0 (0.8-1.0) 1.3 (1.1-1.6)* 4.4 (4.2-5.0) 3.1 (2.8-3.3) 1.4 (1.2-1.7) 1.0 (0.9-1.2) .68
Control 1.0 (0.7-1.3) 1.7 (1.5-2.1)* 4.8 (3.9-5.6) 3.0 (2.5-4.3) 1.2 (1.1-1.5) 1.0 (0.8-1.1)
Venous potassium (mmol/L)
FDP 3.6 (3.5-3.7) 3.2 (3.0-3.4)* 4.8 (4.6-5.0) 5.3 (4.5-6.9) 4.4 (4.2-4.8) 4.3 (4.0-4.7)† .99
Control 3.6 (3.4-3.8) 3.0 (2.8-3.2)* 5.1 (4.7-5.4) 4.9 (4.4-5.3) 4.9 (4.7-5.1) 4.9 (4.6-5.6)†
Values are shown as medians with interquartile ranges (25th-75th percentile). P values between groups are according to the tests of between-subjects
effects.
*P  .05 interaction between time versus baseline and other intervals in the study groups.
†P  .01 interaction between time versus baseline and other intervals in the study groups.
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organs, such as the heart,2-4 and this ultimately has an
impact on the outcome after such a severe period of global
ischemia.
The mechanism of action of FDP is still unclear. In
addition to its function as a regulator of glycolysis through
stimulation of phosphofructokinase, FDP may affect glyco-
lysis by acting as an alternative metabolic substrate.4 It may
bypass the reaction involving phosphofructokinase and in-
crease ATP production. Thus FDP administration could
preserve cellular energy stores during periods of hypoxia
and reestablish cellular energy production after a period of
hypoxia. This speculation is supported by the results of this
study, which showed increased brain glucose and pyruvate
levels and a higher brain pyruvate-lactate ratio during the
reperfusion period in the FDP-treated animals than in the
control animals.
The glycolysis-related mode of action assumes that ex-
ogenous FDP enters the cell. FDP traditionally has been
thought to be unable to cross the cell membrane. However,
there is some indirect evidence supporting the ability of
FDP to enter the cell.2,3,5,15 In addition to its stimulating
effect on carbohydrate metabolism through its glycolysis-
related mode of action,16 other interesting mechanisms of
action have been suggested to be involved in the protective
effects of FDP against ischemic cell injury. FDP is able to
regulate ion flow across cell membranes, and it has been
shown to reduce the ischemia-induced intracellular accumu-
lation of calcium1,2 and to enhance the uptake of potassium,
thus reducing intracellular sodium concentration and cyto-
toxic edema.17 Moreover, FDP has been shown to inhibit
the generation of oxygen free radicals by activated neutro-
phils during ischemia and reperfusion18 and to increase red
blood cell deformability, thus decreasing blood viscosity.19
FDP has also been shown to protect cerebrovascular endo-
Figure 3. Electrolytes and osmolarity in FDP (squares) and control (circles) groups. Data points represent medians;
error bars represent interquartile ranges (25th-75th percentile). Asterisk indicates P < .05 for interaction between
time versus baseline and other intervals in study groups; double asterisk indicates P < .01 for interaction between
time versus baseline and other intervals in study groups. A, Osmolarity; B, venous sodium; C, venous phosphate;
D, venous ionized calcium.
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Figure 4. Results of brain microdialysis and intracranial pressure measurements in FDP (squares) and control
(circles) groups. Data points represent medians; error bars represent interquartile ranges (25th-75th percentile). P
values represent interaction between time versus baseline and other intervals in study groups. A, Brain glucose;
B, brain lactate; C, brain pyruvate; D, brain glutamate; E, brain glycerol; F, intracranial pressure.
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thelial cells from hypoxic injury,20 thus possibly improving
cerebral blood flow during reperfusion after an ischemic event.
Although a body of evidence strongly suggests a neuro-
protective effect of FDP against brain ischemic injury, there
have been studies in which FDP failed to ameliorate hy-
poxic ischemic injury.8,9 However, species and animal age
differences as well as differences in timing of FDP admin-
istration and schedules of ischemia could explain these
discrepancies.
In this study with a surviving porcine model of HCA, a
distinct protective effect of FDP after global ischemia was
observed in terms of survival, behavioral score, and his-
topathologic appearance. The overall survival could have
been affected not only by preservation of neuronal function
but also by protection of other vital organs, such as the heart
and the lungs. However, significant differences between the
groups in terms of cardiac index, mean arterial pressure,
oxygen consumption, and oxygen delivery were not ob-
served. This could be because of the calcium-chelating
activity of FDP, which has been suggested to be one of the
major mechanisms underlying its protective effect on myo-
cardium exposed to a period of ischemia. Such a negative
inotropic effect, in fact, is counterbalanced by a decrease in
serum calcium and thus by a reduction of calcium overload
after reperfusion, which is a well-known mechanism under-
lying ischemia-reperfusion cell injury.21,22 The relatively
short-term postoperative monitoring of the latter parame-
ters, however, precludes any conclusion regarding the ef-
fects of FDP after the first 8 hours from the end of HCA. On
the other hand, FDP was associated with a decrease in
postoperative serum CK-MB level, an observation that con-
firms the myocardial protective effects of this drug and
possibly its effects also on other tissues exposed to pro-
longed systemic ischemia.
FDP was associated with an increase in blood PCO2 and
also with increases in brain pyruvate and lactate concentra-
tions, presumably as a result of increased energy metabo-
lism through the glycolytic pathway. The administration of
FDP led to a notable serum phosphate load, which resulted
in a marked decrease in serum ionized calcium levels,
probably as a result of the calcium-chelating effect of phos-
phate. This FDP-related effect has also been observed in
other studies.2,7,8,21 However, such a decrease in serum
ionized calcium did not result in a major negative inotropic
effect on myocardium, with cardiac index and mean arterial
pressure of the FDP group similar to those observed in the
placebo group. Peripheral vascular resistance was slightly
decreased in the FDP group, probably because of FDP’s
calcium-chelating effect. This negative inotropic effect, as
discussed previously, is associated with evident beneficial
effects in terms of reduction of ischemia-reperfusion cell
injury.21 The observation that calcium uptake in the brain
correlates directly with plasma calcium levels22 suggests
that such a calcium-chelating effect of the drug is likely to
have lessened the detrimental effect of calcium influx into
the neurons as well as into the myocardial cells.
The higher sodium content in the trisodium salt of FDP
used in this study, as opposed to the physiologic level in the
saline solution in the control group, led to significantly
higher blood sodium levels and osmolarity and thus to a
Figure 5. EEG burst recovery in pigs after 75 minutes of HCA in FDP (squares) and control (circles) groups.
Burst-suppression ratio  [EEG burst time/(EEG burst time  EEG suppression time)]  100. Data points represent
medians; error bars represent interquartile ranges (25th-75th percentile).
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more favorable fluid balance in the FDP-treated animals
throughout the postoperative period. This observation could
argue against the metabolic effects of FDP and rather sug-
gest an antiedemigenic effect of this drug. In the FDP-
treated group, a decrease in intracranial pressure was ob-
served only during the rewarming period. Although we can
not entirely prove this contention, the increased osmolarity
cannot be considered to be the main contributor to brain
protection because of its extremely time-limited effect on
intracranial pressure. Indeed, FDP was associated with in-
tracranial pressure levels that were the same or slightly
higher than those in the control animals during most of the
postoperative period.
The tendency toward higher brain levels of glucose,
pyruvate, and lactate during the first postoperative hours
suggests an increase in anaerobic metabolism in the FDP
group. Indeed, these findings confirm our previous obser-
vation in a series of 74 animals that underwent a 75-minute
period of HCA in which a temporary increase in brain levels
of glucose and lactate immediately after reperfusion was
significantly associated with a better survival outcome and a
reduced risk of brain infarction.23 It has been shown that
glucose is consumed anaerobically by astrocytes producing
lactate, which in turn is consumed aerobically by neurons
after a period of hypoxia.24-26 Indeed, it seems that aerobic
use of lactate, and not of glucose, fuels the recovery of
synaptic function during reoxygenation.24 Bliss and Sapol-
sky25 showed that lactate inhibits glucose uptake in cultured
hippocampal neurons after hypoxia-ischemia. Marrif and
Juurlink26 demonstrated that astrocytes have upward regu-
lation of anaerobic glycolytic capacity during hypoxia. This
enables them to get enough ATP to survive and to perform
such important functions as potassium and glutamate uptake
from the extracellular space, thus restoring the cerebral
microenvironment after ischemia. Astrocytes can continue
to produce lactate until their own glycogen store or delivery
of glucose is insufficient. Therefore physiologic compensa-
tory glycolysis is not associated with depletion of glucose
from the extracellular space. However, in cases of severe
ischemia and glucose depletion, this coupled astrocytic-
neuronal unit metabolic activity turns to uncompensated
glycolysis. In fact, under these extreme conditions astro-

















1 7 0 0 0 0 0 0
2 7 3 0 0 0 0 3
3 7 4 0 0 0 1 5
4 7 4 0 0 0 0 4
5 2 1 0 0 0 0 1
6 2 1 0 0 0 1 2
7 7 4 2 1 1 1 9
8 7 4 0 3 0 1 8
9 7 1 0 1 0 1 3
10 7 1 0 1 0 0 2
11 7 1 0 0 0 0 1
12 7 1 0 0 1 1 3
Mean 2.08 0.17* 0.50† 0.17 0.5 3.42†
Control
1 7 1 0 0 0 1 2
2 2 1 0 1 0 1 3
3 1 2 2 1 1 1 7
4 1 3 3 3 1 1 11
5 1 1 1 0 0 0 2
6 7 1 0 1 0 1 3
7 1 3 2 3 1 0 9
8 2 3 3 3 1 1 11
9 1 3 3 2 0 1 9
10 7 4 0 1 0 1 6
11 7 4 0 0 0 1 5
12 7 1 3 1 0 0 5
Mean 2.25 1.42* 1.33† 0.33 0.75 6.08†
Signs of brain ischemic injury were scored as follows: 1, dark or eosinophilic neurons or cerebellar Purkinje cells; 2, moderate edema; and 3, severe edema,
infarct foci (local necrosis). The total score is the sum of scores of each specific brain area.
*P  .01 FDP group versus control group.
†P  .05 FDP group versus control group.
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cytes may not provide enough lactate to the neurons, which
may itself revert to glycolysis and compete with astrocytes
for extracellular glucose. The results of this study thus
suggest that FDP may contribute to support the astrocytic-
neuronal unit activity by preserving the ATP content and by
avoiding uncompensated glycolysis.
In conclusion, the intravenous administration of two
500-mg/kg doses of FDP before and after HCA in a surviv-
ing porcine model was associated with better survival, be-
havioral outcome, and histopathologic findings. The ob-
served lower brain glycerol levels and the higher brain
glucose, pyruvate, and lactate levels suggest that this drug
exerts supportive effects on brain metabolism.
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